Arquivos De Gastroenterologia - 50 Anos

Silva, Adávio de Oliveira e

doi:10.1590/s0004-28032013000100001

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The triple therapy (proton pump inhibitor, clarithromycin, and amoxicillin) for seven days has been the most widely used regimen, recommended by many national and international consensus meetings [ 7 , 8 ]. However, over the past several years a considerable drop in the eradication rates of H. pylori has been observed, reaching unacceptable levels (less than 80%) [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Standard Triple Therapy versus Sequential Therapy inHelicobacter pyloriEradication: A Double-Blind, Randomized, and Controlled Trial

Eisig

Navarro–Rodriguez

Teixeira

et al. 2015

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Aim. To compare 10-day standard triple therapy versus sequential therapy as first-line treatment in patients infected with H. pylori. Methods. One hundred H. pylori positive patients (diagnosed by rapid urease test and histology), with average age of 47.2, M/F = 28/72, were randomized to receive either standard triple treatment (TT) as follows: lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g, b.i.d. for ten days, or sequential treatment (ST) as follows: lansoprazole 30 mg, amoxicillin and placebo 1.0 g b.i.d for the first five days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and tinidazole 500 mg b.i.d, for the remaining five days. Eradication rates were determined 60 days after treatment by urease, histology, or 13C-urea breath test. Results. In intention to treat (ITT) analysis, the rate of H. pylori eradication in the TT and ST groups was the same for both regimens as follows: 86% (43/50), 95% CI 93,3 to 73.4%. In Per protocol (PP) analysis, the rate of H. pylori eradication in the TT and ST groups was 87.8% (43/49), 95% CI 94,5 to 75.3% and 89.6% (43/48), 95% CI 95,8 to 77.3%, respectively. Conclusions. In Brazil, standard triple therapy is as equally effective as sequential therapy in eradicating Helicobacter pylori patients. This study was registered under Clinical Trials with number ISRCTN62400496.

show abstract

Section: Introductionmentioning

confidence: 99%

Standard Triple Therapy versus Sequential Therapy inHelicobacter pyloriEradication: A Double-Blind, Randomized, and Controlled Trial

Eisig

Navarro–Rodriguez

Teixeira

et al. 2015

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…The standard quadruple therapy consisting of PPI, bismuth salt, tetracycline, and metronidazole is widely used as the first-line treatment if clarithromycin resistance rate is more than 20%. The 3rd Brazilian consensus, 2013, and Maastricht IV consensus [ 7 , 8 ] also recommended it as a second-line salvage therapy. However, bismuth is not available in many countries; thus, an equally effective non-bismuth-based quadruple therapy is essential for H. pylori treatment [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Second-Line Quadruple Therapies with or without Bismuth forHelicobacter pyloriInfection

Jheng

Shih

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

The bismuth-based quadruple regimen has been applied in Helicobacter pylori rescue therapy worldwide. The non-bismuth-based quadruple therapy or “concomitant therapy” is an alternative option in first-line eradication but has not been used in second-line therapy. Discovering a valid regimen for rescue therapy in bismuth-unavailable countries is important. We conducted a randomized controlled trial to compare the efficacies of the standard quadruple therapy and a modified concomitant regimen. One hundred and twenty-four patients were randomly assigned into two groups: RBTM (rabeprozole 20 mg bid., bismuth subcitrate 120 mg qid, tetracycline 500 mg qid, and metronidazole 250 mg qid) and RATM (rabeprozole 20 mg bid., amoxicillin 1 g bid., tetracycline 500 mg qid, and metronidazole 250 mg qid) for 10 days. The eradication rate of the RBTM and RATM regimen was 92.1% and 90.2%, respectively, in intention-to-treat analysis. Patients in both groups had good compliance (~96%). The overall incidence of adverse events was higher in the RATM group (42.6% versus 22.2%, P = 0.02), but only seven patients (11.5%) experienced grades 2-3 events. In conclusion, both regimens had good efficacy, compliance, and acceptable side effects. The 10-day RATM treatment could be an alternative rescue therapy in bismuth-unavailable countries.

show abstract

Arquivos De Gastroenterologia - 50 Anos

Cited by 2 publications

References 0 publications

Standard Triple Therapy versus Sequential Therapy inHelicobacter pyloriEradication: A Double-Blind, Randomized, and Controlled Trial

Standard Triple Therapy versus Sequential Therapy inHelicobacter pyloriEradication: A Double-Blind, Randomized, and Controlled Trial

Comparison of Second-Line Quadruple Therapies with or without Bismuth forHelicobacter pyloriInfection

Contact Info

Product

Resources

About